KI Health Partners, LLC; New England Institute for Clinical Research

Stamford, Connecticut 06905

0 studies enrolling now · 6 studies all time

What they study most

Alzheimer's Disease, Multiple Sclerosis, Relapsing-Remitting

Studies at this site

• Study to Evaluate the Effectiveness and Safety of Ocrelizumab in Participants With Early Stage Relapsing Remitting Multiple Sclerosis (RRMS) — Stopped early
• A Study of Semorinemab in Patients With Moderate Alzheimer's Disease — Completed
• A Study to Evaluate the Efficacy and Safety of Semorinemab in Patients With Prodromal to Mild Alzheimer's Disease — Stopped early
• A Study of Crenezumab Versus Placebo to Evaluate the Efficacy and Safety in Participants With Prodromal to Mild Alzheimer's Disease (AD) — Stopped early
• A Study of Ocrelizumab in Participants With Relapsing Remitting Multiple Sclerosis (RRMS) Who Have Had a Suboptimal Response to an Adequate Course of Disease-Modifying Treatment (DMT) — Completed
• Longitudinal Evaluation of [18F]GTP1 as a PET Radioligand for Imaging Tau in the Brain of Participants With Alzheimer's Disease Compared to Healthy Participants — Completed